A new clinical review explores the complexities of treating psoriasis during pregnancy and lactation highlighting limited ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

A new King’s College London study links abdominal fat—not general obesity—to increased psoriasis risk, especially in women, ...

By Lori Solomon HealthDay ReporterTUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

BELLY fat increases your risk of the skin condition psoriasis, a study warns. Psoriasis, which affects one in 50 people – ...

STOCKHOLM, Sweden, 24th May 2025 - (Nasdaq First North: LIPI) reports negative results from a Phase III clinical study of the AKP02G2 cutaneous spray for mild to moderate plaque psoriasis. The study, ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Let’s discuss four foods to avoid with psoriasis that may be affecting your skin, along with healthier substitutes.

Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...